BioNano Genomics (NASDAQ:BNGO) released its earnings results on Thursday. The company reported ($0.62) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.48) by ($0.14), Morningstar.com reports. The company had revenue of $4.01 million for the quarter, compared to analysts’ expectations of $3.71 million.

Shares of BioNano Genomics stock opened at $4.20 on Friday. The company has a current ratio of 5.19, a quick ratio of 4.72 and a debt-to-equity ratio of 0.59. BioNano Genomics has a 52-week low of $3.50 and a 52-week high of $10.00.

A number of institutional investors have recently made changes to their positions in the business. Millennium Management LLC bought a new stake in BioNano Genomics in the 4th quarter valued at $254,000. Worth Venture Partners LLC increased its holdings in BioNano Genomics by 1,666.6% in the 4th quarter. Worth Venture Partners LLC now owns 79,902 shares of the company’s stock valued at $417,000 after buying an additional 75,379 shares during the period. Monashee Investment Management LLC increased its holdings in BioNano Genomics by 50.6% in the 4th quarter. Monashee Investment Management LLC now owns 245,860 shares of the company’s stock valued at $1,288,000 after buying an additional 82,595 shares during the period. Federated Investors Inc. PA bought a new stake in BioNano Genomics in the 3rd quarter valued at $56,704,000. Finally, Sio Capital Management LLC bought a new stake in BioNano Genomics in the 3rd quarter valued at $7,353,000. 11.50% of the stock is currently owned by hedge funds and other institutional investors.

Several equities analysts recently commented on the stock. Zacks Investment Research cut shares of BioNano Genomics from a “hold” rating to a “sell” rating in a research note on Wednesday, November 28th. ValuEngine lowered shares of BioNano Genomics from a “buy” rating to a “hold” rating in a report on Friday, December 21st. Maxim Group raised shares of BioNano Genomics to a “buy” rating and set a $11.00 price target on the stock in a report on Wednesday, March 6th. Finally, Roth Capital reissued a “buy” rating on shares of BioNano Genomics in a report on Tuesday, February 5th.

COPYRIGHT VIOLATION WARNING: “BioNano Genomics (BNGO) Announces Quarterly Earnings Results, Misses Estimates By $0.14 EPS” was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this story on another publication, it was stolen and republished in violation of international copyright legislation. The correct version of this story can be viewed at https://www.thecerbatgem.com/2019/03/15/bionano-genomics-bngo-announces-quarterly-earnings-results-misses-estimates-by-0-14-eps.html.

About BioNano Genomics

Bionano Genomics, Inc operates as a life sciences instrumentation company in the genome analysis space. The company develops and markets the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes, which is known as cytogenetics.

Read More: Why is the price-sales ratio important?

Receive News & Ratings for BioNano Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioNano Genomics and related companies with MarketBeat.com's FREE daily email newsletter.